DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-438

Reliant Pharmaceuticals, LLC
Attention: Keith S. Rotenberg, Ph.D.
110 Allen Road
Liberty Corner, NJ 07938

Dear Dr. Rotenberg:

Please refer to your new drug application (NDA) dated October 31, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for InnoPran XL (propranolol hydrochloride) Extended Release 80 and 120 mg Capsules.

We acknowledge receipt of your submissions dated January 9, August 30, September 4, October 1, 10 (two), 22, 28 and 29 and November 26, 2002; January 29 and March 4, 2003.

The November 26, 2002 submission constituted a complete response to our August 30, 2002 action letter.

This new drug application provides for the use of InnoPran XL (propranolol hydrochloride) Extended Release 80 and 120 mg Capsules for Hypertension.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted March 4, 2003 and immediate container labels submitted March 4, 2203). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

At the time of the next printing, please make the following changes:

Package Insert

1. In the **DESCRIPTION** section, delete the second sentence of the third paragraph, (b)(4)---------- (b)(4)----------

2. In the **DESCRIPTION** section, change the second sentence of the first paragraph from:

   (b)(4)----------
   -
   To:

   InnoPran XL is available as 80 mg and 120 mg capsules which contain sustained-release beads.

3. In the **DESCRIPTION** section, change the wording of the last sentence of the third paragraph from (b)(4)------o "120 mg."

4. In the **PHARMACOKINETICS AND DRUG METABOLISM/Drug Interactions/***Interactions with Substrates, Inhibitors or Inducers of Cytochrome P-450 Enzymes* subsection, please change the word (b)(4)---to "affect".

5. In the **PHARMACOKINETICS AND DRUG METABOLISM/Drug Interactions** section, reorder the subheadings under *Non-Cardiovascular Drugs* so that they are in alphabetical order.

6. In the **PHARMACOKINETICS AND DRUG METABOLISM/Drug Interactions/***Non-Cardiovascular Drugs*/*Anti-Ulcer Drugs* section, delete the words (b)(4)----------in the second paragraph from:

7. Correct spelling error in the section title, **PHARMACODYNAMICS AND CLINICAL EFFECTS**.

8. In the **PHARMACOKINETICS AND DRUG METABOLISM/Special Populations/Race** section, change (b)(4)----------to "Whites" in the last sentence.

9. In the **PRECAUTIONS/Drug Interactions** section, reorder the subheadings under **Cardiovascular Drugs** so that they are in alphabetical order.

10. In the **PRECAUTIONS/Drug Interactions** section, reorder the subheadings under **Non-Cardiovascular Drugs** so that they are in alphabetical order.

11. In the **PRECAUTIONS/Carcinogenesis, Mutagenesis, Impairment of Fertility** section and **PRECAUTIONS/Pregnancy: Pregnancy Category C** section, change (b)(4)----------to "propranolol HCl" wherever it occurs.

Container labeling

1. Revise immediate container labels so the boldness in type is consistent across dosage strengths and labeling provisions. It is noted that on certain 120 mg strength labeling text is relatively faint.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-438**." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Cardio-Renal Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

Your stability data supports an expiration date of (b)months for the drug product packaged in blister configurations and 1(b months for the drug product packaged in the HDPE bottles.

Reference to the (b)(4)----------nformation should be deleted with appropriate revision of the stability pr--------

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

{See appended electronic signature page}

Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Doug Throckmorton

3/12/03 12:55:05 PM